Defining conditions for covalent immobilization of angiogenic growth factors onto scaffolds for tissue engineering

Journal of Tissue Engineering and Regenerative Medicine

Volumn 5, Issue 1, 2011, Pages 69-84

  Chiu, Loraine L Y ^a   Weisel, Richard D ^a   Li, Ren Ke ^a   Radisic, Milica ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiopoietin 1; Collagen; Covalent immobilization; Endothelial cell; Scaffold; Tissue engineering; Vascular endothelial growth factor

Indexed keywords

CELL ENGINEERING; CELL IMMOBILIZATION; CELL PROLIFERATION; COLLAGEN; ENDOTHELIAL CELLS; MASS TRANSFER; REACTION RATES; SCAFFOLDS (BIOLOGY); TISSUE;

ANGIOPOIETIN-1; ANGIOPOIETINS; COLLAGEN SCAFFOLDS; COVALENT IMMOBILIZATION; ENDOTHELIAL-CELLS; IMMOBILISATION; PHOSPHATE-BUFFERED SALINES; REACTION BUFFER; TISSUES ENGINEERINGS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

METABOLISM;

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; ANGIOPOIETIN 1; CD31 ANTIGEN; COLLAGEN; LACTIC ACID; PHOSPHATE BUFFERED SALINE; TISSUE SCAFFOLD; VASCULOTROPIN;

ANIMAL CELL; AORTA; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMOBILIZATION; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE ENGINEERING;

EID: 78650283515     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.292     Document Type: Article

References (40)

1. Arsic N, Zentilin L, Zacchigna S, et al. 2003; Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther 7: 450-459.
2. Backer MV, Patel V, Jehning BT, et al. 2006; Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. Biomaterials 27: 5452-5458.
3. Benest AV, Salmon AH, Wang W, et al. 2006; VEGF and angiopoietin-1 stimulate different angiogenic phenotypes that combine to enhance functional neovascularization in adult tissue. Microcirculation 13: 423-437.
4. Boontheekul T, Mooney DJ. 2003; Protein-based signaling systems in tissue engineering. Curr Opin Biotechnol 14: 559-565.
5. Chang PV, Prescher JA, Sletten EM, et al. 2010; Copper-free click chemistry in living animals. Proc Natl Acad Sci USA 107: 1821-1826.
6. Chen HK, Hung HF, Shyu KG, et al. 2005; Combined cord blood stem cells and gene therapy enhances angiogenesis and improves cardiac performance in mouse after acute myocardial infarction. Eur J Clin Invest 35: 677-686.
7. Chen PR, Chen MH, Lin FH, Su WY. 2005; Release characteristics and bioactivity of gelatin-tricalcium phosphate membranes covalently immobilized with nerve growth factors. Biomaterials 26: 6579-6587.
8. Cheng M, Park H, Engelmayr GC, et al. 2007; Effects of regulatory factors on engineered cardiac tissue in vitro. Tissue Eng 13: 2709-2719.
9. Chiu LLY, Radisic M. 2010; Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues. Biomaterials 31: 226-241.
10. DeBusk LM, Hallahan DE, Lin PC. 2004; Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res 298: 167-177.
11. Delomenie C, Goodfellow GH, Krishnamoorthy R, et al. 1997; Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. Biochem J 323(1): 207-215.
12. Fan VH, Tamama K, Au A, et al. 2007; Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. Stem Cells 25: 1241-1251.
13. Goerges AL, Nugent MA. 2003; Regulation of vascular endothelial growth factor binding and activity by extracellular pH. J Biol Chem 278: 19518-19525.
14. Grabarek Z, Gergely J. 1990; Zero-length crosslinking procedure with the use of active esters. Anal Biochem 185: 131-135.
15. Hashimoto M, Hara T, Honda M, et al. 1992; Metabolic aspects of endothelial cells cultured from rat aortae. Artery 19: 284-296.
16. Hosack LW, Firpo MA, Scott JA, et al. 2008; Microvascular maturity elicited in tissue treated with cytokine-loaded hyaluronan-based hydrogels. Biomaterials 29: 2336-2347.
17. Ito Y. 2008; Covalently immobilized biosignal molecule materials for tissue engineering. Soft Matter 4: 46-56.
18. Ito Y, Hasuda H, Terai H, Kitajima T. 2005; Culture of human umbilical vein endothelial cells on immobilized vascular endothelial growth factor. J Biomed Mater Res A 74: 659-665.
19. Kim I, Ryu YS, Kwak HJ, et al. 2002; EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB J 16: 1126-1128.
20. Kim SH, Kiick KL. 2007; Heparin-mimetic sulfated peptides with modulated affinities for heparin-binding peptides and growth factors. Peptides 28: 2125-2136.
21. Koblizek TI, Weiss C, Yancopoulos GD, et al. 1998; Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol 8: 529-532.
22. Koch S, Yao C, Grieb G, et al. 2006; Enhancing angiogenesis in collagen matrices by covalent incorporation of VEGF. J Mater Sci Mater Med 17: 735-741.
23. Kutryk MJ, Stewart DJ. 2003; Angiogenesis of the heart. Microsc Res Tech 60: 138-158.
24. Leclerc C, Brose C, Nouze C, et al. 2008; Immobilized cytokines as biomaterials for manufacturing immune cell based vaccines. J Biomed Mater Res A 86: 1033-1040.
25. Lee HS, Kim KS, Kim CJ, et al. 2009; Electrical detection of VEGFs for cancer diagnoses using anti-vascular endotherial growth factor aptamer-modified Si nanowire FETs. Biosens Bioelectron 24: 1801-1805.
26. Lee KW, Yoon JJ, Lee JH, et al. 2004; Sustained release of vascular endothelial growth factor from calcium-induced alginate hydrogels reinforced by heparin and chitosan. Transpl Proc 36: 2464-2465.
27. Mizuno T, Yau TM, Weisel RD, et al. 2005; Elastin stabilizes an infarct and preserves ventricular function. Circulation 112: I81-88.
28. Olde Damink LH, Dijkstra PJ, van Luyn MJ, et al. 1996; Cross-linking of dermal sheep collagen using a water-soluble carbodiimide. Biomaterials 17: 765-773.
29. Otto K, Elwing H, Hermansson M. 1999; Effect of ionic strength on initial interactions of Escherichia coli with surfaces, studied on-line by a novel quartz crystal microbalance technique. J Bacteriol 181: 5210-5218.
30. Satchell SC, Anderson KL, Mathieson PW. 2004; Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15: 566-574.
31. Shen YH, Shoichet MS, Radisic M. 2008; Vascular endothelial growth factor immobilized in collagen scaffold promotes penetration and proliferation of endothelial cells. Acta Biomater 4: 477-489.
32. Shyu KG, Chang H, Isner JM. 2003; Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci 73: 563-579.
33. Silva AK, Richard C, Bessodes M, et al. 2009; Growth factor delivery approaches in hydrogels. Biomacromolecules 10: 9-18.
34. Steffens GC, Yao C, Prevel P, et al. 2004; Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. Tissue Eng 10: 1502-1509.
35. Taguchi T, Kishida A, Akashi M, Maruyama I. 2000; Immobilization of human vascular endothelial growth factor (VEGF165) onto biomaterials: an evaluation of the biological activity of immobilized VEGF165. J Bioact Compat Polym 15: 309-320.
36. Vepari CP, Kaplan DL. 2006; Covalently immobilized enzyme gradients within three-dimensional porous scaffolds. Biotechnol Bioeng 93: 1130-1137.
37. 2/glass composite Ecopore with heparinized collagen and the osteoinductive factor BMP-2. Acta Biomater 4: 997-1004.
38. Wissink MJ, Beernink R, Poot AA, et al. 2000; Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J Control Release 64: 103-114.
39. Zacchigna S, Tasciotti E, Kusmic C, et al. 2007; In vivo imaging shows abnormal function of vascular endothelial growth factor-induced vasculature. Hum Gene Ther 18: 515-524.
40. Zhou L, Ma W, Yang Z, et al. 2005; VEGF165 and angiopoietin-1 decreased myocardium infarct size through phosphatidylinositol-3 kinase and Bcl-2 pathways. Gene Ther 12: 196-202.